Although we identified BRD4 degradation as a therapeutic means of eliminating T-ALL LICs, our gene array data raise concerns about upregulated CXCR4, other microenvironment niche molecules, and Wnt/β-catenin signaling after BRD4 degradation. The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.